195 related articles for article (PubMed ID: 18990887)
21. [Dyspepsia and heartburn in primary care: a rational and economic approach].
Labenz J
MMW Fortschr Med; 2009 Aug; 151(34-35):47-8. PubMed ID: 19771792
[No Abstract] [Full Text] [Related]
22. Proton pump inhibitor utilization patterns in infants.
Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of pantoprazole in the therapy of esophageal reflux disease].
Lazebnik LB; Vasil'ev IuV
Eksp Klin Gastroenterol; 2008; (2):102-4. PubMed ID: 19145874
[No Abstract] [Full Text] [Related]
24. [Graded therapy in reflux disease. "In severe cases 40 mg., in milder 20 mg."].
Gillessen A
MMW Fortschr Med; 2004 Mar; 146(11):54. PubMed ID: 15152771
[No Abstract] [Full Text] [Related]
25. [Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma].
Popadynets' IR
Lik Sprava; 2013 Sep; (6):47-53. PubMed ID: 25510089
[TBL] [Abstract][Full Text] [Related]
26. All PPIs equivalent for treatment of GERD.
J Fam Pract; 2005 Dec; 54(12):1024. PubMed ID: 16370078
[No Abstract] [Full Text] [Related]
27. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
Gillessen A
MMW Fortschr Med; 2010 May; 152(18):52. PubMed ID: 20514766
[No Abstract] [Full Text] [Related]
29. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
30. [Focus on multi-morbidity patients. Considering the greatest measure of therapy safety].
MMW Fortschr Med; 2007 Dec; 149(49-50):59. PubMed ID: 18236986
[No Abstract] [Full Text] [Related]
31. [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Garrido A; Iborra MI; Saperas E; de Sousa M;
Med Clin (Barc); 2010 May; 134(13):577-82. PubMed ID: 20189198
[TBL] [Abstract][Full Text] [Related]
32. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Choi HS; Park DI; Hwang SJ; Park JS; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
Helicobacter; 2007 Dec; 12(6):638-42. PubMed ID: 18001407
[TBL] [Abstract][Full Text] [Related]
33. [When sour does not make merry at all . Fast relief for patients with reflux].
MMW Fortschr Med; 2003 Apr; 145(15):64. PubMed ID: 15104274
[No Abstract] [Full Text] [Related]
34. [Stubborn reflux pain, inconspicuous esophagus. Which therapy brings the fastest relief?].
MMW Fortschr Med; 2004 Mar; 146(11):54. PubMed ID: 15152770
[No Abstract] [Full Text] [Related]
35. [Therapeutic innovations in gastroesophageal reflux].
Bigard MA
Presse Med; 2007 Dec; 36(12 Pt 3):1907-12. PubMed ID: 17531431
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
37. Latin american consensus on gastroesophageal reflux disease: an update on therapy.
Cohen H; Tomasso G; Luisa Cafferata M; Zapata C; Sharma P; Armstrong D; Moraes-Filho JP; Blasco C; Corti R; Estape G; Leite Luna L; Ortuño R; Sakai P; Salis G; Taullard D; Trakal E; Valdovinos M; Vergara M; Gónzalez O
Gastroenterol Hepatol; 2010 Feb; 33(2):135-47. PubMed ID: 19664853
[No Abstract] [Full Text] [Related]
38. Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Petryszyn P; Staniak A; Grzegrzolka J
J Comp Eff Res; 2016 Mar; 5(2):169-78. PubMed ID: 26946951
[TBL] [Abstract][Full Text] [Related]
39. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
Scholten T; Dekkers CP; Schütze K; Körner T; Bohuschke M; Gatz G
Digestion; 2005; 72(2-3):76-85. PubMed ID: 16113546
[TBL] [Abstract][Full Text] [Related]
40. [Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
Sharova EP
Eksp Klin Gastroenterol; 2008; (6):74-6. PubMed ID: 19334429
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
